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Abstract
Leishmaniasis is a neglected tropical disease (NTDs), endemic in 88 countries, affecting more than 12 million people. The
treatment consists in pentavalent antimony compounds, amphotericin B, pentamidine and miltefosine, among others.
However, these current drugs are limited due to their toxicity, development of biological resistance, length of treatment and
high cost. Thus, it is important to continue the search for new effective and less toxic treatments. The anti-Leishmania
activity of sixteen semisynthetic lupane triterpenoids derivatives of betulin (BT01 to BT09) and betulinic acid (AB10 to AB16)
were evaluated. Drug interactions between the active compounds and one current antileishmanial drug, miltefosine, were
assessed using the fixed ratio isobologram method. In addition, effects on the cell cycle, apoptosis/necrosis events,
morphology and DNA integrity were studied. The derivatives BT06 (3b-Hydroxy-(20R)-lupan-29-oxo-28-yl-1H-imidazole-1-
carboxylate) and AB13 (28-(1H-imidazole-1-yl)-3,28-dioxo-lup-1,20(29)-dien-2-yl-1H-imidazole-1-carboxylate) were found to
be the most active, with IC50 values of 50.8 mM and 25.8 mM, respectively. Interactions between these two compounds and
miltefosine were classified as synergistic, with the most effective association being between AB13 and miltefosine, where
decreases of IC50 values to 6 mM were observed, similar to the miltefosine activity alone. AB13 induced significant
morphological changes, while both derivatives produced anti-proliferative activity through cell cycle arrest at the G0/G1
phase. Neither of these derivatives induced significant apoptosis/necrosis, as indicated by phosphatidylserine
externalization and DNA fragmentation assays. In addition, neither of the derivatives induced death in macrophage cell
lines. Thus, they do not present any potential risk of toxicity for the host cells. This study has identified the betulin
derivative BT06 and the betulinic acid derivative AB13 as promising molecules in the development of new alternative
therapies for leishmaniasis, including those involving combined-therapy with miltefosine.
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Introduction
Over one billion people are infected by one or more neglected
tropical diseases (NTDs). These diseases comprise a group of
parasitic, viral and bacterial infections that affect some of the
poorest and most marginalized populations globally. Leishmani-
asis is one such NTD that is endemic in 88 countries, affecting
more than 12 million people and threatening 350 million people
worldwide. The disease is associated with an incidence of 1.5 to 2
million cases per year, and an annual mortality rate of over 59,000
deaths [1]. It is caused by the Leishmania species, and the disease is
broadly classified into three different clinical forms: visceral
leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocuta-
neous leishmaniasis (MCL), which differ in the pattern and clinical
manifestations of infection. VL can be fatal if left untreated, CL is
localized and frequently self-heals within 3–18 months, while
MCL leaves disfiguring scars. The parasite growth occurs through
different morphological stages: the flagellated promastigotes
develop in the gut of the phlebotomine sandfly female (vector),
while the non-flagellated amastigotes develop in mammalian host
macrophages.
Currently, the treatment consists of chemotherapeutic agents,
such as the pentavalent antimony compounds (sodium stiboglu-
conate or meglumine antimoniate), polyene amphotericin B (as the
deoxycholate salt or a liposomal formulation, AmBisome), the
alkylphosphocholine miltefosine, aminoglycoside paromomycin
and pentamidine [2]. All of these are limited due to their high
toxicity, life-threatening side-effects, cost, length of treatment and
emergence of resistance [1,3]. Because of the limited viable
treatment options, with few alternatives available in the pipeline, it
is important to continue the search for new effective chemother-
apeutics and less toxic treatments.
The development of drug resistance is associated with mono-
therapy regimes [3,4]. Combination therapy is one interesting
approach to decrease this development, to reduce the duration
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and cost of the treatment, and to increase the lifetime of old and
new drugs [5,6]. Several combined treatments for visceral
leishmaniasis have been tested with positive results, leading to a
reduction of adverse symptoms and a shorter duration of therapy
[7].
Figure 1. Structures of betulin derivatives and IUPAC nomenclature.
doi:10.1371/journal.pone.0089939.g001
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Recent pharmacological studies elicited interest in several
molecules with activities that trigger apoptotic death in cancerous
cells as potential antiparasitic agents [8]. In trypanosomatids,
features suggesting programmed cell death (PCA), commonly
named as apoptosis, have been reported in response to a wide
range of stimuli such as heat shock, reactive oxygen species,
antiparasitic drugs, prostaglandins, and antimicrobial peptides [9–
11]. There are several reports showing that Leishmania apoptosis
occur in response to antileishmanial drugs. The treatment with the
pentavalent antimony Sb(V) shows a significant induction of
caspase-like activity resulting in DNA fragmentation [12].
Inhibitors of respiratory chain complexes were able to induce
apoptotic cell death on the blood stream form of L. donovani [13].
Topoisomerase I poison camptothecin, promotes protein-DNA
cleavable complex formation leading to apoptosis-like cell death in
Leishmania donovani [14,15]. Miltefosine, the latest antileishmanial
drug introduced in the market and the first effective oral treatment
of VL, was initially developed as an anticancer drug [16] and
induce apoptosis-like cell death in Leishmania donovani [17]. All these
findings point the importance of testing known anticancer agents
against Leishmania due of its potential to inducing parasite death.
Triterpenoids in general, and particularly betulin and its
derivative betulinic acid, show antitumor [18–20], anti-inflamma-
tory [21,22], antiviral [19,23,24], antibacterial and antimalarial
activity [25,26]. There are few studies in literature reporting the
activity of betulin and betulinic acid derivatives in Leishmania.
Alakurtti and collaborators [27] determined the activity of
heterocyclic betulin derivatives on Leishmania donovani amastigotes
and Dominguez-Carmona and collaborators [28] found activity
against promastigotes of L. amazonensis of betulinic acid acetate and
of betulinic acid methyl ester.
Figure 2. Structures of betulinic acid derivatives and IUPAC nomenclature.
doi:10.1371/journal.pone.0089939.g002
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Previously, a series of new imidazole carboxylic esters (carba-
mates) and N-acylimidazole derivatives of betulin and betulinc
acid have been synthesized and were showed to have cytotoxicity
activity against human cancer cell lines HepG2, Jurkat and HeLa
[29]. This cytotoxicity was related with apoptosis mechanisms
associated with caspases signalling and DNA topoisomerases
inhibition [30,31]. These results prompt us to evaluate their
potential activity on Leishmania. We studied the susceptibility of
Leishmania infantum to sixteen betulin and betulinic acid derivatives,
together with the interactions between the most active compounds
and miltefosine. Additionally, we have undertaken other assays to
demonstrate the safety of the triterpenoid compounds for
mammalian cells, and to elucidate the mechanisms of action
involved in the leishmanicidal activity.
Materials and Methods
Chemicals and reagents
RPMI-1640 Medium, Phosphate Buffered Saline (PBS), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
dimethylsulfoxide (DMSO) were obtained from Sigma–Aldrich
Co. Fetal bovine serum (FBS) was purchased from Gibco-
Invitrogen.
Drugs and inhibitors
Miltefosine was obtained from Sigma Chemical Co.(St.
Louis,USA). The nine derivatives of betulin (Figure 1) and the
seven betulinic acid derivatives (Figure 2) used in this study were
previously synthesized as part of a large library of compounds for
potential antitumor evaluation [29]. The stock solutions (10 mM)
derivatives of betulin and betulinic acid were prepared in
dimethylsulfoxide (DMSO) and stored at 220uC. A stock solution
of miltefosine (10 mM) was prepared in deionizer water and stored
at 4uC. Final DMSO concentration (1%) had no effect on parasite
clearance.
Parasites and cultures
Promastigote forms of Leishmania infantum Nicolle (zymodeme
MON-1) were maintained at 26uC with weekly transfers in
HEPES (25 mM)-buffered RPMI 1640 medium enriched with
10% inactivated fetal bovine serum (FBS). Log phase promasti-
gotes were used to study the effects of the betulin and betulinic
acid derivatives, miltefosine and drug combinations.
Viability assay
In drug susceptibility assays, stock solutions of betulin and
betulinic acid derivatives were diluted in culture medium (RPMI
1640) in order to get a range of concentrations from 1 to 100 mM.
Log phase promastigotes of L. infantum (26106 cells.ml21) were
incubated at 26uC for 24 h in HEPES (25 mM)-buffered RPMI
1640 medium enriched with 10% inactivated FBS in the presence
of increasing concentrations of the derivatives or different
concentration of DMSO (maximum of 1% as controls).
The effect on the cells viability was tested by MTT (3-[4, 5-
methylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) colorimet-
ric method, based on the reduction of the tetrazolium dye to
insoluble formazan by the mitochondrial enzymes [32]. Briefly,
25 ml of MTT (5 mg.ml21) was added to each well, incubated for
2 h at 37uC and centrifuged at 3000 rpm for 5 min. The
supernatant was removed, the cells were washed in PBS, and
the precipitated formazan was dissolved in DMSO (250 ml). Cell
viability was measured by absorbance at 530 nm on an ELISA
plate reader (Synergy HT, Bio-TEK), and calculated using the
following formula: [(L2/L1)6100], where L1 is the absorbance of
control cells and L2 is the absorbance of treated cells. Three
separate experiments were performed for each drug and the
concentration that inhibited viability by 50% (IC50) was
determined through dose-response regression analysis, plotted by
GraphPad Prism 5.
Isobologram construction and classification of the nature
of drug interaction
For the most active betulin and betulinic acid derivatives,
combinations were made with them at growing concentrations and
Figure 3. Effects of betulin (A) and betulinic acid (B) derivatives
on Leishmania infantum promastigotes viability. Cultures of log-
phase promastigotes (26106 cells.ml21) were incubated at 26uC for
24 h at different drug concentrations. Values are expressed as means
and SEM.
doi:10.1371/journal.pone.0089939.g003
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miltefosine at fixed concentrations and cells viability was evaluated
by MTT as described above.
Classical isobolograms were constructed by plotting drugs
concentrations (alone and in combination) that inhibits 50%
trophozoites viability, as previously described [33]. The isobolo-
gram analysis evaluates the nature of interaction of two drugs, i.e.,
drug A and drug B. First, the concentrations of drugs A and B
required to produce a defined single-agent effect (e.g., IC50), when
used as single agents, are placed on the x and y axes in a two-
coordinate plot, corresponding to (CA, 0) and (0, CB), respectively.
The line connecting these two points is the line of additivity.
Second, the concentrations of the two drugs used in combination
to provide the same effect, denoted as (cA, cB), are placed in the
same plot. Synergy, additivity, or antagonism are indicated when
(cA, cB) is located below, on, or above the line, respectively.
Morphological studies
L. infantum promastigotes were exposed to the most active
betulin and betulinic acid derivatives and the morphological
alterations were investigated by optical microscopy using direct
examination of live microorganism (hanging drop) and after
Giemsa stain. Briefly, exponentially grown of L. infantum promas-
tigote (26106 cells.ml21) were treated with BT06 and AB13 at
IC50 concentrations for 2 h, 4 h, 6 h and 24 h at 26uC. After
incubation, cells were pelleted by centrifugation at 3000 rpm for
5 min and the supernatant was discarded by aspiration. The cell
pellet was suspended in fresh medium and approximately 10 mL
was placed on a Koch slide and directly observed under the optical
microscope phase contrast (Eclipse E400, Nikon coupled with a
digital camera 165 DN100 Nikon). In addition, a smear was made
which was submitted to Giemsa stain. The smear was fixed with
Figure 4. Effects of combinations of betulin and betulinic acid derivatives with miltefosine on Leishmania infantum promastigotes
viability. (A) Betulin derivative BT06; (B) Betulinic acid derivative AB13. Values are expressed as means and SEM. Cultures of log-phase promastigotes
(26106 cells.ml21) were incubated at 26uC for 24 h at different compound concentrations.
doi:10.1371/journal.pone.0089939.g004
Table 1. Inhibitory concentrations at 50% (IC50) of the association between betulin and acid betulinic derivatives (BT06, AB13)
with miltefosine on Leishmania infantum promastigotes.
Drug combination IC50 mM (CI)* R
2
BT06 50.8 (46,9–55.0) 0.85
+miltefosine 2 mM 30.1 (27,2–33.4) 0.94
+miltefosine 4 mM 25.9 (20,1–33.3) 0.81
AB13 25.8 (23,3–28.7) 0.92
+miltefosine 2 mM 7.6 (5,8–10.0) 0.87
+miltefosine 4 mM 6.0 (5,3–6.7) 0.93
Miltefosine 7.6 (6,6–8.8) 0.93
* CI, confidence interval at 95%.
doi:10.1371/journal.pone.0089939.t001
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methanol for 5 min, stained with aqueous solution of Giemsa (1/
10, v/v) for 10 min at room temperature and finally washed with
water and air dried. The stained smear was observed under the
microscope with a 1006 lens (Eclipse E400, coupled with Nikon
digital camera, Nikon DN100 165).
Cell cycle analysis
For analysis of DNA content, exponentially grown of L. infantum
(26106. cells ml21) were treated with BT06 and AB13 at IC50
concentrations for 2 h, 4 h, 6 h and 24 h at 26uC. At each time
point, cells were fixed in 200 ml of 70% ethanol for 30 min. at 4uC.
After washing cells with 2 mL of PBS, enriched with 2% of bovine
serum albumin (BSA), the pellets were suspended in 0.5 mL of PI
solution (PI/Rnase, Immunostep) and incubated for 15 minutes at
37uC [34]. Cells were then analyzed by flow cytometry
(FacsCalibur-Beckton-Dickinson). Results were treated using
ModFit LT V 2.0 programme.
Phosphatidylserine externalization
Double staining for annexin V-FITC and propidium iodide (PI)
was performed as described previously [35]. Briefly, L. infantum
promastigotes (26106 cells.ml21) were exposed to BT06 and AB13
at IC50 concentrations for 2 h, 4 h, 6 h, and 24 h at 26uC. Cells
were then washed with PBS and ressuspendedn in binding buffer
(10 mM HEPES–NaOH, pH 7.4, 140 NaC1, 2.5 mM CaCI2).
To 100 ml of this suspension were added 5 ml of Annexin VFITC
and 5 ml of PI (AnnexinV-FITC Apoptosis detection Kit,
Immmunostep). After 15 min incubation in the dark at room
temperature, it was added 400 ml binding buffer and cells were
analyzed by flow cytometry (FacsCalibur–Beckton–Dickinson).
Data analysis was carried out using the program Paint-a-gate, and
values are expressed as a percentage of positive cells for a given
marker, relatively to the number of cells analyzed.
Figure 5. Comparison of the effects of combinations between BT06 and miltefosine with the effects of BT06 alone. Cultures of log-
phase promastigotes (26106 cells.ml21) were incubated at 26uC for 24 h. Significance level of *p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0089939.g005
Figure 6. Comparison of the effects of combinations between AB13 and miltefosine with the effects of AB13 alone. Cultures of log-
phase promastigotes (26106 cells.ml21) were incubated at 26uC for 24 h. Significance level of *p,0.05, **p,0.01 and ***p,0.001.
doi:10.1371/journal.pone.0089939.g006
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DNA fragmentation assay
Promastigotes of L. infantum (26106 cells.ml21) were exposed to
IC50 concentration of the most active betulin and betulinic acid
derivatives or to dissolution vehicle (DMSO), and incubated at
26uC for 24 hours. The Leishmania DNA extraction was carried out
according to the procedure in DNeasy Blood & Tissue (Qiagen).
Figure 7. Isobologram analysis for the combinations between BT06 and miltefosine (A) and AB13 and miltefosine (B). The line
indicates synergy, additivity or antagonism when the points are located below, on or above the line, respectively. (a) derivative and 2 mM miltefosine;
(b) derivative and 4 mM miltefosine; (c) derivative and 6 mM miltefosine.
doi:10.1371/journal.pone.0089939.g007
Figure 8. Optical microscopy observation of Leishmania infantum promastigotes in the absence and presence of the betulinic acid
derivative AB13. Hanging dropin phase contrast (A, B, magnification 2006) and Giemsa staining (C, D, magnification 10006). Control cells
incubated with DMSO at 26uC for 24 h (A, C). Cells exposed to the AB13 derivative at 26uC for 24 h (B, D).
doi:10.1371/journal.pone.0089939.g008
Antileishmanial Activity of Triterpenoids
PLOS ONE | www.plosone.org 7 March 2014 | Volume 9 | Issue 3 | e89939
DNA integrity analysis was done by electrophoresis, running DNA
through an EtBr-treated agarose gel and visualizing it with UV
light.
Mammalian cell cytotoxicity
For cytotoxicity assays on mammalian cells, log phase of
macrophages (RAW 264.7) were trypsinized and incubated at
37uC in 24-well tissue culture plates in Dulbecco’s Modified Eagle
Medium (DMEM), enriched with Glutamax and supplemented
with 10% fetal bovine serum (FBS), under microaerophilic
condition. As soon as the monolayers reached confluence, the
medium was removed and the cells were incubated at 37uC for
24 h with fresh medium plus the betulin or betulinic acid
derivatives at IC50 concentrations. After incubation, control and
treated cells were washed with PBS, pH 7.2., and 450 ml of PBS
and 50 ml MTT solution (5 mg.ml21) were added to each well and
incubated at 37uC for 1 h. The cells were then washed with PBS,
500 ml DMSO was added to the wells and absorbance was
measured at 530 nm on an ELISA plate reader (Synergy HT, Bio-
TEK). The percentage of viable cells was determined as described
on viability assay.
Statistical analysis
All experiments were performed in triplicate. The mean and
standard deviation (SEM) of three independent assays were
determined and statistical analysis between mean values was done
by ANOVA test, with a Dunnett’s post-test. The significance level
was *p,0.05, **p,0.01 and ***p,0.001.
Results and Discussion
This study considers the biological potential of the betulin and
betulinic acid derivatives, and is aimed at the evaluation of the
anti-Leishmania activity of 16 synthetic derivatives of betulin (BT01
to BT09) and betulinic acid (AB10 to AB16). This is followed by a
study of the association of the most active derivatives with
miltefosine, a drug used in the treatment of leishmaniasis. The
activity of the derivatives on L. infantum was assessed by cell
viability studies. At the highest concentrations, all nine betulin
derivatives inhibit promastigote viability (Figure 3A). Generally,
the results showed that modifications at C-20 (compounds BT06
and BT07, Figure 1) and at C-30 (compound BT05, Figure 1) have
a positive impact on the anti-leishmanial activity of betulin
derivatives. The introduction of a carbamate moiety at C-28 in the
C-3 substituted derivative BT02 (Figure 1) afforded compound
BT03 with lower anti-leishmanial activity (Figure 3A). The betulin
derivative BT06 (3b-Hydroxy-(20R)-lupan-29-oxo-28-yl-1H-imid-
azole-1-carboxylate) was found to be the most effective, with an
IC50 of 50.8 mM. The other derivatives did not inhibit the growth
of L. infantum by 50% at the highest concentration tested (100 mM).
Of the seven betulinic acid derivatives (Figure 3B), the most
active compound was AB13 (28-(1H-imidazole-1-yl)-3,28-dioxo-
lup-1,20(29)-dien-2-yl-1H-imidazole-1-carboxylate), with an IC50
of 25.8 mM. The remaining betulinic acid derivatives were not
able to inhibit viability of L. infantum by 50% at the highest
concentrations tested (100 mM), however, compounds AB14 with
an a,b-unsaturated keto group at ring A (Figure 2), AB15 and
AB11 with a keto group and carbamate moiety at C-3 (Figure 2),
respectively, showed moderate anti-leishmanial activity. The
introduction of the imidazole and methyl esther at C-28 in
compounds AB12 and AB16 (Figure 2) respectively, reduce the
anti-leishmanial activity (Figure 3B), when compared with
derivative AB11 bearing a free carboxylic acid at C-28 position
(Figure 2).
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The best activity of AB13 compound, is consistent with
published results that report a higher biological activity of
betulinic acid derivatives compared with betulin ones [19,31].
The superior anti-Leishmania activity of the AB13 derivative could
be associated with the higher capacity as a Michael acceptor of this
derivative. Considering the Michael addition reaction and
according to Sporn and collaborators [36], one possible biological
mechanism of action of AB13 may be related to the nucleophilic
attack from thiol groups of reduced glutathione or other
physiological nucleophiles, including amine nucleophiles, to the
a-b-unsaturated-keto group (C1 in ring A) (Figure 2).
The interpretation of results and comparisons between drug
activity studies need to take into account the Leishmania species and
the parasite model cells, i.e., promastigotes or amastigotes. There
are only a few reports on the activity of betulin and betulinic acid
derivatives in Leishmania donovani amastigotes (IC50 values of 8.9 to
30 mM) [27] and on promastigotes of L. amazonensis (IC50 of
44.9 mM to 69.9 mM) [28]. Comparing these with the present
data, we observe that BT06 and AB13 derivatives show
antileishmanial activity that is similar or higher than that described
for the other triterpenoids. In addition, as well as being active
against promastigote cells, BT06 and AB13 are expected to exhibit
stronger activity on amastigote forms, as tends to be found among
natural extracts and synthetic drugs [37–41].
It is important in the discovery of new drugs that a molecule
with anti-Leishmania activity does not impart significant toxicity to
the host cells. In this study, we have evaluated the toxicity of the
most active derivatives in a macrophage cell line (RAW 264.7). We
found that BT06 and AB13 derivatives, at IC50 concentrations,
were not cytotoxic toward the macrophage cell line, suggesting
Figure 9. Representative cell cycle histograms of Leishmania infantum. Promastigotes were incubated at 26uC for 24 h in the absence (A and
C) or presence of betulin derivative BT06 (B) and betulinic acid derivative AB13 (D) at IC50 concentrations. Propidium iodide staining was performed
and samples were analyzed by flow cytometry.
doi:10.1371/journal.pone.0089939.g009
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that they are safe for mammalian cells. Therefore, the two
triterpenoides are promising compounds for the discovery of new
drugs against Leishmania infections.
For each of the two most active derivatives (BT06 and AB13),
three different combinations at fixed concentrations of miltefosine
(2, 4 and 8 mM) were tested. Dose-response curves showed that the
combinations of BT06/miltefosine and AB13/miltefosine were
more effective at reducing the viability of promastigotes relative to
the derivatives alone (Figure 4). The IC50 values obtained for all
the tested combinations were less than the values obtained for the
pure derivatives (Table 1). The combination of the betulin
derivative BT06 with miltefosine at 2 mM and 4 mM induced
decreases of the IC50 value from 50,8 mM to 30,1 mM and
25,9 mM, respectively. The combination of the betulinic acid
derivative AB13 with miltefosine at 2 mM and 4 mM induced
decreases of the IC50 value from 25,8 mM to 7,6 mM and 6,0 mM,
respectively.
The statistical differences between the effects of the combina-
tions of the derivatives BT06 and AB13 with miltefosine and the
effects of the derivatives alone were analyzed. The combinations
between BT06 and miltefosine (Figure 5) induced a significant
reduction (p,0.05, p,0.01 and p,0.001) on promastigote
viability relative to the BT06 activity, except for the combination
BT06 10 mM with miltefosine 2 mM. The association AB13 and
miltefosine is most effective, with high statistical significance (p,
0.01 and p,0.001) in all combinations when compared with the
effects of the derivative alone (Figure 6). Isobolographic analysis
showed that all the interactions of AB13 and BT06 with
miltefosine were synergistic, with experimental values (a, b, c)
below the theoretical IC50 values (line of additivity) (Figure 7). The
advantages of combination therapy include increased effectiveness
of the drug, reduced dosage, decreased toxicity and a delay or
prevention of the onset of drug resistance [3]. The derivatives
show a synergistic association with miltefosine, therefore they
could be promising molecules for the development of new
combination therapies for leishmaniasis.
In this work, we have also looked at the mechanisms of action
responsible for the biological activity in Leishmania of the most
active betulin and betulinic acid derivatives (BT06 and AB13).
The effects on morphology, apoptosis/necrosis events, DNA
integrity and cell cycle were studied. The morphological modifi-
cations were evaluated by optical microscopy using direct
examination of live microorganism (hanging drop) and after
Giemsa stain. Control cells were very mobile with the character-
istic fusiform shape (Figure 8A), while after Giemsa staining it was
possible to observe the characteristic shape, long flagellum
emerging from the anterior region of the parasite, nucleus and
kinetoplast, posterior to the nucleus (Figure 8C). With the BT06
derivative, no significant morphologic alterations were observed
(not shown). However, the promastigotes exposed to AB13
suffered significant morphological changes (Figure 8 B,D) com-
pared with the control. These cells showed a marked decrease in
mobility, and it was possible to observe changes in the size and
shape of the promastigotes, which become smaller and rounder
(Figure 8B). The Giemsa stained promastigotes also show
alterations in flagellum size (Figure 8D). These effects suggest that
the leishmanicidal activity of the AB13 derivative may be
associated with changes in the cytoskeletal organization and
function, and modification of the activity of mitochondrial
bioenergetics.
Cell death by apoptosis/necrosis was assessed by flow cytometry
using Annexin V/PI labeling and the study of the DNA integrity.
During early apoptosis, phosfatidilserine (PS) is translocated from
the cytoplasmic face of the plasma membrane to the external face,
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which can be detected using Annexin V. To distinguish apoptotic
cell death from necrotic cell death, cells were counterstained with
PI, a non-permeable stain with an affinity for nucleic acids, as it
selectively enters necrotic cells. Therefore, co-staining of annexin
V and PI can differentiate between cells undergoing early
apoptosis (annexin V+/PI2), necrosis or late apoptosis (PI+/
annexin V2) and live cells (PI2/annexin V2). The Leishmania
promastigote cells treated during 24 hours with BT06 and AB13
did not show significant differences in annexine V and PI staining
compared with the respective controls (Table 2).
The cell cycle analysis was performed by flow cytometry after PI
staining of the parasites incubated with betulin derivative BT06
and betulinic acid derivative AB13 for 24 h at IC50 concentrations
(Table 3). Figure 9 shows the distribution of cell DNA trough cell
cycle of parasites in the absence and presence of the BT06 and
AB13. After 24 h of incubation, the majority of treated parasite
cells were on G0/G1 phase of cell cycle (BT06, 67.7%; AB13,
81.2%), which is the opposite of what occurs in non-treated cells
(44.2% and 48%, respectively). Both derivatives promoted
retention of L. infantum promastigotes in the G0/G1 phase of the
cell cycle, suggesting an arrest at this stage of the cycle. We
observed a marked reduction in DNA replication and mitosis, with
a decrease in the number of cells in G2/M phase and S phase
mainly with the derivative AB13. Inhibition of L. infantum
promastigote proliferation seems to represent a major mechanism
of activity of derivatives BT06 and AB13.
It was reported that dihydrobetulinic acid (DHBA), a derivative
of betulinic acid, is an excellent inhibitor of Leishmania DNA
topoisomerase I and II and induces apoptosis in L. donovani [42].
More recently, it was shown that three betulin derivatives
(disuccinyl betulin, diglutaryl dihydrobetulin, and disuccinyl
dihydrobetulin) inhibit both growth of Leishmania donovani, and
relaxation activity of the enzyme type IB topoisomerase of the
parasite (topoisomerase I; LdTOP1LS) [43]. Considering these
potential therapeutic targets in Leishmania and based on our results,
we suggest that Leishmania DNA topoisomerases could be a
potential target for BT06 and AB13 derivatives. This hypothesis is
also supported in the previous antiproliferative activity of AB13
and BT06 derivatives on cancer cell lines and on their inhibitory
proprieties on DNA topoisomerase [29–31].
In conclusion, the betulin derivative BT06 and betulinic acid
derivative AB13 are promising lead compounds which can be used
in the discovery of new therapies for Leishmania infections,
including multidrug treatment schedules with miltefosine.
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